Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, James I. Mullins, Brian Simpkins et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) studyNigel Garrett, Moelo Malahleha, Asa Tapley et al.|EClinicalMedicine|2025Cited by 5
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVNonhlanhla N. Mkhize, Sinead Delany‐Moretlwe, Bo Zhang et al.|Nature Communications|2025Cited by 1
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIVVimla Naicker, Nonhlanhla N. Mkhize, Philip Kotze et al.|UNC Libraries|2025Cited by 0
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresLawrence Corey, Carolyn Williamson, Hong Zhao et al.|Carolina Digital Repository (University of North Carolina at Chapel Hill)|2025Cited by 0